Rob Brierley,Hugh Thomas
Rob Brierley
The role of primary care in response to the global liver disease syndemic: a Lancet Gastroenterology & Hepatology Commission [0.03%]
柳叶刀胃肠病和肝病委员会：初级保健在全球肝脏疾病大流行中的作用
Helen Jarvis,Paul N Brennan,Teresa Casanovas et al.
Helen Jarvis et al.
Liver disease causes substantial global morbidity and mortality, with a growing burden from steatotic liver disease driven by alcohol use and metabolic dysfunction, alongside persisting challenges from chronic viral hepatitis. Liver disease...
Dupilumab versus placebo in adults and adolescents with eosinophilic gastritis (DEGAS): a double-blind, placebo-controlled, phase 2, multicentre, randomised controlled trial [0.03%]
dupilumab与安慰剂治疗嗜酸细胞性胃炎成人及青少年患者(DEGAS)：一项多中心、随机、双盲、安慰剂对照II期临床试验
Nirmala P Gonsalves,Evan S Dellon,Kara L Kliewer et al.
Nirmala P Gonsalves et al.
Background: Eosinophilic gastritis currently has no approved treatments and is postulated to be driven by type 2 inflammation. Dupilumab blocks type 2 cytokines IL-4 and IL-13 and has efficacy in multiple diseases charact...
Addition of ipilimumab to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma (PRODIGE 81-FFCD 2101-TRIPLET HCC): phase 2 results from a randomised, multicentre, open-label, phase 2-3 trial [0.03%]
纳武利尤单抗联合阿特珠单抗和贝伐珠单抗治疗晚期肝细胞癌的II期疗效观察(PRODIGE 81-FFCD 2101-TRIPLET HCC II/III期研究)
Philippe Merle,Jean-Frederic Blanc,Karine Le Malicot et al.
Philippe Merle et al.
Background: Patients with unresectable hepatocellular carcinoma have a poor prognosis and treatments with long-term benefits are needed. Anti-PD-L1 or anti-PD-1 plus anti-VEGF or anti-CTLA-4 double combinations are valida...
Balancing benefit and burden: rethinking post-polypectomy colonoscopy surveillance strategies [0.03%]
获益和负担的平衡：重新思考结肠镜检查术后结直肠癌筛查策略
Joep E G IJspeert,Michael Bretthauer,Rodrigo Jover et al.
Joep E G IJspeert et al.
Post-polypectomy colonoscopy surveillance is widely implemented to reduce colorectal cancer incidence and mortality, yet increasing evidence raises concerns about whether current strategies are optimally balanced in terms of benefit, burden...
HLA-DRB1*01:03 in patients with inflammatory bowel disease: a genotype-phenotype association study [0.03%]
炎症性肠病患者中HLA-DRB1*01:03基因型与表型关联研究
Qian Zhang,Eathar Shakweh,Mohmmed Tauseef Sharip et al.
Qian Zhang et al.
Background: The association between HLA-DRB1*01:03 and severe ulcerative colitis has long been recognised. However, the recent discovery of an association with neutralising auto-antibodies against IL-10 raises new questio...
Li-You Lian,Wen-Yue Liu,Wenhao Li et al.
Li-You Lian et al.
EASL Congress 2026 [0.03%]
2026年EASL大会
Rob Brierley
Rob Brierley